Your browser doesn't support javascript.
loading
Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Theiner, Sarah; Varbanov, Hristo P; Galanski, Mathea Sophia; Egger, Alexander E; Berger, Walter; Heffeter, Petra; Keppler, Bernhard K.
Afiliación
  • Theiner S; Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, 1090, Vienna, Austria.
  • Varbanov HP; Research Platform 'Translational Cancer Therapy Research', University of Vienna, Waehringer Strasse 42, 1090, Vienna, Austria.
  • Galanski MS; Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, 1090, Vienna, Austria.
  • Egger AE; Institute of Inorganic Chemistry, University of Vienna, Waehringer Strasse 42, 1090, Vienna, Austria.
  • Berger W; ADSI-Austrian Drug Screening Institute GmbH, Innrain 66a, 6020, Innsbruck, Austria.
  • Heffeter P; Research Platform 'Translational Cancer Therapy Research', University of Vienna, Waehringer Strasse 42, 1090, Vienna, Austria.
  • Keppler BK; Department of Medicine I, Comprehensive Cancer Center of the Medical University, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
J Biol Inorg Chem ; 20(1): 89-99, 2015 01.
Article en En | MEDLINE | ID: mdl-25413442
Platinum(IV) complexes are promising candidates as prodrugs for oral application in anticancer chemotherapy. However, only a few Pt(IV) compounds entered (pre)clinical trials, e.g. satraplatin, while most of the others were only tested in vitro. Aim of the study was investigation of the in vivo pharmacological behavior as well as the anticancer activity of two novel platinum(IV) complexes vs. satraplatin. The drugs were selected due to significantly different in vitro cytotoxicity while sharing some physicochemical properties (e.g. lipophilicity). Initial experiments indicated that the highly in vitro cytotoxic compound 1 ((OC-6-33)-dichloridobis((4-ethoxy)-4-oxobutanoato)-bis(ethylamine)platinum(IV)) was also characterized by high drug absorption and tissue platinum levels after oral application. Interestingly, analysis of serum samples using SEC-ICP-MS revealed that the administered drugs have completely been metabolized and/or bound to proteins in serum within 2 h after treatment. With regard to the activity in vivo, the outcomes were rather unexpected: although potent anticancer effect of 1 was observed in cell culture, the effects in vivo were rather minor. Nevertheless, 1 was superior to 2 ((OC-6-33)-diammine(cyclobutane-1,1-dicarboxylato)-bis((4-cyclopentylamino)-4-oxobutanoato)platinum(IV)) after i.p. administration, which was, at least to some extent, in accordance to the cell culture experiments. After oral gavage, both compounds exhibited comparable activity. This is remarkable considering the distinctly lower activity of 2 in cell culture as well as the low platinum levels detected both in serum and tissues after oral application. Consequently, our data indicate that the prediction of in vivo anticancer activity by cell culture experiments is not trivial, especially for orally applied drugs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organoplatinos / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Biol Inorg Chem Asunto de la revista: BIOQUIMICA Año: 2015 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organoplatinos / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Biol Inorg Chem Asunto de la revista: BIOQUIMICA Año: 2015 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Alemania